ライフサイエンスコーパス: L-PAM

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します

1 L-PAM analysis also pinpointed microvessels ablated or r

2 L-PAM mapped microvascular architecture and quantified v

3 L-PAM was administered at target temperature; WBH was ad

4 alan (L-PAM) in seven L-PAM-sensitive and 11 L-PAM-resistant neuroblastoma cell lines.

5 In addition, L-PAM failed to up-regulate TNF-alpha expression in sple

6 Dose-related neutropenia required an L-PAM dose reduction to 10 mg/m2 at BSO 7.5 g/m2.

7 to receive either L-PAM alone on week 2 and L-PAM plus WBH on week 5, or the reverse sequence.

8 ount and platelet nadirs for L-PAM alone and L-PAM plus WBH demonstrated that the addition of WBH res

9 e for the curative effectiveness of low dose L-PAM for mice bearing a large MOPC-315 tumor by demonst

10 rtance of the B7-2 molecule for the low dose L-PAM-induced acquisition of the ability of tumor-infilt

11 ndent tumor-eradicating immunity in low dose L-PAM-treated mice bearing a large MOPC-315 tumor, sugge

12 cells from the s.c. tumor nodule of low dose L-PAM-treated MOPC-315 tumor bearers and the selective u

13 the percentage of mice cured by the low dose L-PAM.

14 age of mice than that observed with low-dose L-PAM alone.

15 improves the therapeutic outcome of low-dose L-PAM for MOPC-315 tumor bearers by inhibiting IL-10 sec

16 n of neutralizing anti-IL-10 mAb to low-dose L-PAM-treated MOPC-315 tumor bearers (administration of

17 n of neutralizing anti-IL-10 mAb to low-dose L-PAM-treated MOPC-315 tumor bearers was comparable to t

18 ovide added therapeutic benefits to low-dose L-PAM-treated MOPC-315 tumor bearers.

19 r patients were randomized to receive either L-PAM alone on week 2 and L-PAM plus WBH on week 5, or t

20 ns of mean WBC count and platelet nadirs for L-PAM alone and L-PAM plus WBH demonstrated that the add

21 IFN-beta in turn plays an important role in L-PAM-induced TNF-alpha up-regulation.

22 d/or MDM2 proteins in response to melphalan (L-PAM) in seven L-PAM-sensitive and 11 L-PAM-resistant n

23 er the same BSO as cycle one with melphalan (L-PAM) 15 mg/m2 i.v. 1 hour after the fifth dose.

24 Longitudinal photoacoustic microscopy (L-PAM) was coincidentally developed for noninvasive, lab

25 low-dose melphalan (L-phenylalanine mustard (L-PAM))-treated MOPC-315 tumor bearers led to IL-10 secr

26 low dose melphalan (L-phenylalanine mustard; L-PAM) therapy of hitherto immunosuppressed mice bearing

27 -dose of melphalan (L-phenylalanine mustard; L-PAM) to mice bearing a large s.c. MOPC-315 tumor leads

28 Toxicities allowed for escalation of L-PAM to 20 mg/m2; all four patients at this level exper

29 Dose levels of L-PAM were 10 mg/m2 (n = 3), 15 mg/m2 (n = 3), 17.5 mg/m

30 The pharmacokinetics of L-PAM were not altered by WBH.

31 nvolved in the transcriptional regulation of L-PAM-induced IFN-beta gene expression.

32 rated clinical improvement received WBH plus L-PAM monthly.

33 ns in response to melphalan (L-PAM) in seven L-PAM-sensitive and 11 L-PAM-resistant neuroblastoma cel

34 We conclude that L-PAM with 41.8 degrees C WBH is well tolerated.

35 The L-PAM-induced accumulation of IFN-beta mRNA was mimicked

36 in in turn was found to be important for the L-PAM-induced up-regulation of TNF-alpha expression, as

37 as neutralization of IFN-beta inhibited the L-PAM-induced up-regulation of TNF-alpha mRNA expression

38 t p53, causing high-level drug resistance to L-PAM, carboplatin, and etoposide.

39 sponse gene that is activated in response to L-PAM via a pathway that involves reactive oxygen specie

40 Studies into the mechanism through which L-PAM leads to rapid accumulation of IFN-beta mRNA revea

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。